Abstract 587P
Background
HER2 is known for its oncogenic activities in diverse cancers, including non-small cell lung cancer (NSCLC). Despite its significance, the prevalence of HER2 alterations in Malaysian NSCLC patients remains unreported. This study examined the prevalence and characteristics of HER2 mutations in a Malaysian cohort.
Methods
Next-generation sequencing (NGS) results of NSCLC samples received from October 2019 to December 2022, were assessed to determine the prevalence of HER2 mutations and amplification, along with the patient characteristics.
Results
Out of 1373 cases analyzed, 79 patients (5.8%) exhibited HER2 alterations, with HER2 mutations (n=54, 3.9%), HER2 amplification (20, 1.5%), and mutation with amplification (5, 0.4%) being identified. Patients with HER2 mutations were significantly younger than non-HER2-mutant counterparts (median age 61 vs. 64 years old; p=0.046) and displayed a tendency to be female and never-smokers (not statistically significant, NS). Patients with HER2 amplification tended to be male and ex- or current smokers (NS). Furthermore, HER2 amplification was associated with post-TKI progression (p=0.015). HER2 exon 20 insertions were the most common HER2 mutations, affecting 47/59 patients. Notably, HER2 Y772_A775dup was the most frequently detected variant (n=34). HER2 exon 20 insertions were mutually exclusive with ALK, BRAF, EGFR, RET, ROS1 and MET alterations. Two patients with HER2 Y772_A775dup harboured KRAS alterations, one with KRAS amplification and the other KRAS K117N. EGFR sensitizing mutations were observed in 4 patients with HER2 S310S/Y variants. Eleven patients with HER2 amplification had EGFR sensitizing mutation; of these, 5 were post-TKI progression cases. TP53 mutations were common co-mutations seen with HER2 mutation (n=14) and HER2 amplification (9).
Conclusions
This prevalence of HER2 mutations was 4.3% and HER2 amplification was 1.8% in this cohort of Malaysian patients with NSCLC. These findings suggest that the availability of HER2-targeted therapies may hold promise for managing these patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
AstraZeneca.
Disclosure
P. Rajadurai: Financial Interests, Personal, Speaker, Consultant, Advisor: AstraZenaca, Novartis, MSD; Financial Interests, Personal, Invited Speaker: ThermoFisher; Financial Interests, Institutional, Research Grant: AstraZeneca, Roche. All other authors have declared no conflicts of interest.
Resources from the same session
496P - Fruquintinib plus sintilimab in patients (pts) with advanced non-small cell lung cancer (NSCLC) with PD-L1-positive expression: A multicenter, single-arm phase II study
Presenter: Shun Lu
Session: Poster Display
Resources:
Abstract
497P - Sintilimab in combination with anlotinib in advanced NSCLC treated with first-line PD-1 antibodies: An open, single-arm, phase II trial
Presenter: Ying Jin
Session: Poster Display
Resources:
Abstract
498P - Frailty-adjusted life expectancy and survival in older lung cancer patients: A large-scale electronic health-record based study
Presenter: Thao Tu
Session: Poster Display
Resources:
Abstract
499P - Long-term survival and treatment (tx) patterns after first-line (1L) osimertinib in patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive (m) advanced non-small cell lung cancer (NSCLC): Japanese cohort of a global real-world (rw) observational study
Presenter: Daichi Fujimoto
Session: Poster Display
Resources:
Abstract
500P - The effectiveness and safety of durvalumab after chemoradiotherapy for locoregional recurrence of completely resected non-small cell lung cancer: Real-world, multicenter, observational study (NEJ056)
Presenter: Hidehito Horinouchi
Session: Poster Display
Resources:
Abstract
501P - One-year survival outcomes of unresectable stage III non-small cell lung cancer patients who underwent PD-1 inhibitor plus chemo as induction therapy
Presenter: Xin Wang
Session: Poster Display
Resources:
Abstract
502P - Impact of sarcopenia on the outcome of patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy followed by durvalumab
Presenter: Kentaro Tamura
Session: Poster Display
Resources:
Abstract
503P - Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with locally advanced NSCLC
Presenter: TSUYOSHI HIRATA
Session: Poster Display
Resources:
Abstract
504P - Real-world outcomes with induction systemic therapy for stage III in eligible for upfront local therapy: Pre vs post immunotherapy era in a tertiary referral centre
Presenter: Praveen Kumar Marimuthu
Session: Poster Display
Resources:
Abstract
505P - Neoadjuvant PD-1 inhibitor (tislelizumab) plus platinum–etoposide in patients with limited-stage small cell lung cancer: A phase II trial
Presenter: Junjie Hu
Session: Poster Display
Resources:
Abstract